ATE198830T1 - Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems - Google Patents
Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystemsInfo
- Publication number
- ATE198830T1 ATE198830T1 AT92907711T AT92907711T ATE198830T1 AT E198830 T1 ATE198830 T1 AT E198830T1 AT 92907711 T AT92907711 T AT 92907711T AT 92907711 T AT92907711 T AT 92907711T AT E198830 T1 ATE198830 T1 AT E198830T1
- Authority
- AT
- Austria
- Prior art keywords
- nervous system
- degenerative diseases
- pct
- treat degenerative
- anabaseine
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000653 nervous system Anatomy 0.000 title 1
- AUBPMADJYNSPOA-UHFFFAOYSA-N Anabaseine Chemical compound C1CCCC(C=2C=NC=CC=2)=N1 AUBPMADJYNSPOA-UHFFFAOYSA-N 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- KHUUTHZSRXABAC-DTQAZKPQSA-N n,n-dimethyl-4-[(e)-(6-pyridin-3-yl-3,4-dihydro-2h-pyridin-5-ylidene)methyl]aniline Chemical compound C1=CC(N(C)C)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 KHUUTHZSRXABAC-DTQAZKPQSA-N 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66286791A | 1991-03-01 | 1991-03-01 | |
| PCT/US1992/001451 WO1992015306A1 (en) | 1991-03-01 | 1992-02-27 | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE198830T1 true ATE198830T1 (de) | 2001-02-15 |
Family
ID=24659568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92907711T ATE198830T1 (de) | 1991-03-01 | 1992-02-27 | Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US5516785A (de) |
| EP (1) | EP0573568B1 (de) |
| JP (1) | JP2657583B2 (de) |
| KR (2) | KR0137003B1 (de) |
| AT (1) | ATE198830T1 (de) |
| AU (1) | AU652434B2 (de) |
| CA (2) | CA2362719A1 (de) |
| DE (1) | DE69231658T2 (de) |
| DK (1) | DK0573568T3 (de) |
| ES (1) | ES2153357T3 (de) |
| GR (1) | GR3035542T3 (de) |
| WO (1) | WO1992015306A1 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2153357T3 (es) * | 1991-03-01 | 2001-03-01 | Univ Florida | Uso de analogos nicotinicos para el tratamiento de enfermedades degenerativas del sistema nervioso. |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| CA2142610C (en) * | 1992-08-31 | 2003-09-16 | William R. Kem | Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
| US5510355A (en) * | 1994-09-06 | 1996-04-23 | Bencherif; Merouane | Depolarizing skeletal muscle relaxants |
| JP3219946B2 (ja) * | 1994-09-22 | 2001-10-15 | 大鵬薬品工業株式会社 | 新規製造中間体及びピリジン誘導体の製造方法 |
| US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
| ZA984638B (en) | 1997-05-30 | 1998-12-11 | Neurosearch As | Azacyclooctane and heptane derivatives their preparation and use |
| US6350479B1 (en) | 1998-06-05 | 2002-02-26 | Regent Court Technologies | Treating depression with alcohol extracts of tobacco |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| US6750234B2 (en) * | 2001-03-08 | 2004-06-15 | University Of Kentucky Research Foundation | Methods for increasing leptin levels using nicotinic acid compounds |
| US7091357B2 (en) | 2001-12-26 | 2006-08-15 | University Of Kentucky Research Foundation | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| US7160551B2 (en) * | 2002-07-09 | 2007-01-09 | The Board Of Trustees Of The University Of Illinois | Injectable system for controlled drug delivery |
| EP1531820A1 (de) * | 2002-08-30 | 2005-05-25 | Memory Pharmaceuticals Corporation | Anabasein-derivate zur behandlung von neurodegenerativen erkrankungen |
| RU2391341C2 (ru) | 2002-09-25 | 2010-06-10 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение |
| US7736636B2 (en) * | 2003-02-12 | 2010-06-15 | Shaker Mousa | Method for treating occlusive vascular diseases & wound healing |
| CA2463719A1 (en) * | 2003-04-05 | 2004-10-05 | F. Hoffmann-La Roche Ag | Nucleotide analogs with six membered rings |
| US7816356B2 (en) | 2003-11-14 | 2010-10-19 | Daniel Yohannes | Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands |
| NZ550534A (en) | 2004-03-25 | 2009-07-31 | Memory Pharm Corp | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| US20050288333A1 (en) * | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
| KR20060038010A (ko) * | 2004-10-29 | 2006-05-03 | 재단법인서울대학교산학협력재단 | 니코틴산을 포함하는, 갭 결합을 통한 세포간 정보전달의억제 및 항상성의 불균형과 관련된 질환의 예방 또는치료용 조성물 |
| US7930222B2 (en) * | 2006-06-27 | 2011-04-19 | Quiq, Inc. | Method and system for preparing a set of paired identification labels |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| JP2011516489A (ja) * | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2011022467A2 (en) * | 2009-08-21 | 2011-02-24 | University Of Florida Research Foundation, Inc. | Controlled-release formulations of anabaseine compounds and uses thereof |
| AR082138A1 (es) * | 2010-07-12 | 2012-11-14 | Hoffmann La Roche | 1-hidroxiimino-3-fenil-propanos |
| US9440948B2 (en) | 2010-09-03 | 2016-09-13 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| CA2834280C (en) * | 2011-04-28 | 2023-01-10 | Rock Creek Pharmaceuticals, Inc. | Methods of administering anatabine to treat autism spectrum disorders and seizure disorders |
| CN104169269A (zh) | 2011-08-29 | 2014-11-26 | Rcp发展股份有限公司 | 用于抗炎支持的产品 |
| US10340082B2 (en) | 2015-05-12 | 2019-07-02 | Capacitor Sciences Incorporated | Capacitor and method of production thereof |
| US10347423B2 (en) | 2014-05-12 | 2019-07-09 | Capacitor Sciences Incorporated | Solid multilayer structure as semiproduct for meta-capacitor |
| WO2015175558A2 (en) | 2014-05-12 | 2015-11-19 | Capacitor Sciences Incorporated | Energy storage device and method of production thereof |
| RU2017112074A (ru) | 2014-11-04 | 2018-12-05 | Кэпэситор Сайенсиз Инкорпорейтед | Устройства для хранения энергии и способы их получения |
| WO2016138310A1 (en) | 2015-02-26 | 2016-09-01 | Capacitor Sciences Incorporated | Self-healing capacitor and methods of production thereof |
| US9932358B2 (en) | 2015-05-21 | 2018-04-03 | Capacitor Science Incorporated | Energy storage molecular material, crystal dielectric layer and capacitor |
| US9941051B2 (en) | 2015-06-26 | 2018-04-10 | Capactor Sciences Incorporated | Coiled capacitor |
| US10026553B2 (en) * | 2015-10-21 | 2018-07-17 | Capacitor Sciences Incorporated | Organic compound, crystal dielectric layer and capacitor |
| US10305295B2 (en) | 2016-02-12 | 2019-05-28 | Capacitor Sciences Incorporated | Energy storage cell, capacitive energy storage module, and capacitive energy storage system |
| US10153087B2 (en) | 2016-04-04 | 2018-12-11 | Capacitor Sciences Incorporated | Electro-polarizable compound and capacitor |
| US9978517B2 (en) | 2016-04-04 | 2018-05-22 | Capacitor Sciences Incorporated | Electro-polarizable compound and capacitor |
| US11096932B2 (en) | 2016-09-29 | 2021-08-24 | The Uab Research Foundation | Methods and compositions for increasing mucus clearance |
| US10395841B2 (en) | 2016-12-02 | 2019-08-27 | Capacitor Sciences Incorporated | Multilayered electrode and film energy storage device |
| WO2021028005A1 (en) * | 2019-08-15 | 2021-02-18 | Elkazaz Mohamed Fadly Abd El Ghany | A medicament comprising anabasine for treatment of asthma, chest allergy and atopic dermatits |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3247213A (en) * | 1961-04-12 | 1966-04-19 | Shell Oil Co | Heterocyclic nitrogen compounds |
| SU530684A1 (ru) * | 1971-10-27 | 1976-10-05 | Ташкентский Ордена Трудового Красного Знамени Государственный Университет Им.В.И.Ленина | Средство дл лечени хронического никотинизма |
| US4155909A (en) * | 1977-06-13 | 1979-05-22 | Philip Morris Incorporated | 2-Alkyl nicotinoids and processes for their production |
| US4183931A (en) * | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
| US4360531A (en) * | 1981-04-09 | 1982-11-23 | The Upjohn Company | Substituted cycloalkanes |
| US4680172A (en) * | 1985-03-05 | 1987-07-14 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
| US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
| IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
| US5109017A (en) * | 1990-09-26 | 1992-04-28 | Fisons Corporation | (2-thienyl)alkylamine derivatives having neuroprotective properties |
| ES2153357T3 (es) * | 1991-03-01 | 2001-03-01 | Univ Florida | Uso de analogos nicotinicos para el tratamiento de enfermedades degenerativas del sistema nervioso. |
| US5276043A (en) | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
-
1992
- 1992-02-27 ES ES92907711T patent/ES2153357T3/es not_active Expired - Lifetime
- 1992-02-27 KR KR1019930702599A patent/KR0137003B1/ko not_active IP Right Cessation
- 1992-02-27 EP EP92907711A patent/EP0573568B1/de not_active Expired - Lifetime
- 1992-02-27 WO PCT/US1992/001451 patent/WO1992015306A1/en active IP Right Grant
- 1992-02-27 AT AT92907711T patent/ATE198830T1/de active
- 1992-02-27 KR KR1019970708190A patent/KR0175638B1/ko not_active IP Right Cessation
- 1992-02-27 DE DE69231658T patent/DE69231658T2/de not_active Expired - Lifetime
- 1992-02-27 CA CA002362719A patent/CA2362719A1/en not_active Abandoned
- 1992-02-27 JP JP4507369A patent/JP2657583B2/ja not_active Expired - Lifetime
- 1992-02-27 CA CA002105071A patent/CA2105071C/en not_active Expired - Lifetime
- 1992-02-27 US US08/108,663 patent/US5516785A/en not_active Expired - Lifetime
- 1992-02-27 AU AU14556/92A patent/AU652434B2/en not_active Expired
- 1992-02-27 DK DK92907711T patent/DK0573568T3/da active
-
1994
- 1994-09-09 US US08/304,100 patent/US5602257A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/473,667 patent/US6630491B1/en not_active Expired - Lifetime
-
1997
- 1997-02-07 US US08/798,420 patent/US5840906A/en not_active Expired - Lifetime
-
2001
- 2001-03-09 GR GR20010400383T patent/GR3035542T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06509322A (ja) | 1994-10-20 |
| WO1992015306A1 (en) | 1992-09-17 |
| DE69231658T2 (de) | 2001-09-06 |
| AU1455692A (en) | 1992-10-06 |
| DK0573568T3 (da) | 2001-04-23 |
| KR0175638B1 (ko) | 1999-02-18 |
| ES2153357T3 (es) | 2001-03-01 |
| CA2362719A1 (en) | 1992-09-17 |
| US5602257A (en) | 1997-02-11 |
| CA2105071A1 (en) | 1992-09-02 |
| EP0573568B1 (de) | 2001-01-24 |
| CA2105071C (en) | 2002-05-14 |
| EP0573568A1 (de) | 1993-12-15 |
| US6630491B1 (en) | 2003-10-07 |
| KR0137003B1 (ko) | 1998-04-25 |
| EP0573568A4 (en) | 1994-09-21 |
| AU652434B2 (en) | 1994-08-25 |
| DE69231658D1 (de) | 2001-03-01 |
| US5840906A (en) | 1998-11-24 |
| JP2657583B2 (ja) | 1997-09-24 |
| US5516785A (en) | 1996-05-14 |
| GR3035542T3 (en) | 2001-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE198830T1 (de) | Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems | |
| ATE230989T1 (de) | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| DE69329559D1 (de) | Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen | |
| DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| FI942965A0 (fi) | Taimien kasvatusmenetelmä ja -laite | |
| DE69526937T2 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| ATE241981T1 (de) | Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| ATE78162T1 (de) | 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. | |
| DE69431199T2 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen | |
| ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
| MX9202015A (es) | Esteres aril alquilicos de acido 4,5-di hidroxi -9,10- di hidro-9,10-di oxo --2- antracen carboxilico que tienen actividad terapeutica. | |
| ATE203162T1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one | |
| DE69627298D1 (de) | Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten | |
| DE69124382T3 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
| ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE200865T1 (de) | Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien | |
| DE69620394D1 (de) | Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht | |
| DE69627379D1 (de) | Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem | |
| DE59409813D1 (de) | Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen | |
| ATE150645T1 (de) | Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen | |
| ATE167055T1 (de) | 4-guanidinobutyramid zur verbesserung des blutkreislaufs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |